Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Study of VE202 in Mild-to-Moderate Ulcerative Colitis
2021-001280-24Phase 2Active
- Sponsor
- Vedanta Biosciences
- Start
- Aug 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VE202 in autoimmune colitis (3 arms), sponsored by Vedanta Biosciences. Primary endpoints: Endoscopic response rate at Day 56 (8-week VE202 treatment vs placebo) and Endoscopic response rate at Day 56 (2-week VE202 treatment vs placebo). Started Aug 2021; status: active.
02
Drugs
VE202
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-001280-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001280-24.